Experimental treatment helps 2 out of 3 peanut allergy sufferers, study finds
How the study worked
To test the experimental therapy, 66 research centers in 10 countries recruited 554 participants who ranged in age from 4 to 55 and who all had a peanut allergy. Most -- 496 participants -- were between the ages of 4 and 17.
The treatment, which comes in powder-filled capsules, is an oral immunotherapy, and the concept is "treating an allergy by gradually exposing people to the very same thing they're allergic to," Vickery said. Essentially, the treatment is a peanut powder.
Not a cure
Dr. Brian Vickery, the study's lead author, director of the Children's Healthcare of Atlanta Food Allergy Program and an associate professor of pediatrics at the Emory University School of Medicine, cautioned that "it's not a cure."
Link to article in New York Times